Menu

CRISPR Corrects Sickle Cell-Causing Gene in Human Cells

Once implanted in mice, the edited stem cells produced normal hemoglobin.

Oct 13, 2016
Kerry Grens

WIKIMEDIA, DIANA GRIBScientists have used the CRISPR-Cas9 gene-editing technique to rewrite the genetic mutation in blood cells that causes sickle cell disease. Once these treated hematopoietic progenitors, which had been harvested from patients, were given to mice, the cells began to produce healthy hemoglobin.

“What we have right now, if we can scale it up and make sure it works well, is already enough to form the basis of a clinical trial to cure sickle cell disease with gene editing,” study coauthor Mark DeWitt, a postdoctoral fellow at the University of California, Berkeley, told The Los Angeles Times. His team published its results yesterday (October 12) in Science Translational Medicine.

As STAT News pointed out, the technique is not 100 percent efficient. Only a fraction of the treated cells successfully ended up with the right edits; and only 2 percent to 6 percent of the corrected cells retained the edits after 16 weeks once administered to the mice. “A few percent might seem low, said Jacob Corn, scientific director of the [UC Berkeley] Innovative Genomics Initiative and a co-leader of the study, but studies suggest that having just 2 percent to 5 percent of healthy red blood cells could be enough to cure sickle cell,” STAT reported.

Stuart Orkin, a blood stem cell biologist at Harvard Medical School who was not involved in the work, told Chemical & Engineering News that CRISPR is just one route to repair the gene that causes sickle cell anemia. “There is heightened interest given the hoopla around CRISPR/Cas9 but there are other ways to edit,” Orkin said. “Ultimately, the approach that achieves excellent patient outcomes without side-effects is what is desired and there may be several different ways to achieve this end.”

 

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!